Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Earnings Data
Report Date
Feb 25, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.11Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical advancements in Fabry disease and neurology programs, endorsement from the FDA, and an extended cash runway. However, there are ongoing challenges in securing long-term funding and potential regulatory uncertainties. Overall, the highlights outweigh the lowlights, indicating a positive outlook.Company Guidance
Promising Clinical Data in Fabry Disease
Presented detailed clinical data from the registrational STAAR study in Fabry disease, demonstrating the potential for ST-920 as a onetime durable treatment. The FDA reaffirmed the use of eGFR slope as an endpoint to support an accelerated approval pathway.
Advancement in Neurology Pipeline
Commenced patient enrollment in the Phase I/II STAND study for chronic neuropathic pain with ST-503. Also, progressed the prion program towards an anticipated CTA submission in mid-2026.
Extended Cash Runway
Received $6 million from Pfizer's exercise of a buyout option and continued business development discussions. Cash and cash equivalents are expected to fund operations into the first quarter of 2026.
Encouraging Preclinical Data
Presented updated nonclinical data demonstrating durability, potency, and selectivity of ST-503 in nonhuman primates and favorable safety profile.
FDA Endorsement
Received FDA's endorsement on clinical and CMC pathways for Fabry disease, which positively impacts business development discussions.
SGMO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SGMO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $0.55 | $0.46 | -16.36% |
Aug 07, 2025 | $0.48 | $0.46 | -4.17% |
May 12, 2025 | $0.75 | $0.46 | -38.67% |
Mar 17, 2025 | $1.01 | $0.85 | -15.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sangamo Biosciences (SGMO) report earnings?
Sangamo Biosciences (SGMO) is schdueled to report earning on Feb 25, 2026, After Close (Confirmed).
What is Sangamo Biosciences (SGMO) earnings time?
Sangamo Biosciences (SGMO) earnings time is at Feb 25, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SGMO EPS forecast?
SGMO EPS forecast for the fiscal quarter 2025 (Q4) is -0.03.